MBX Biosciences

Update in progress

MBX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

MBX Biosciences is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders. Its lead candidate, Canvuparatide (MBX 2109), is a PTH peptide prodrug in Phase 3 for chronic hypoparathyroidism. Imapextide (MBX 1416) is a long-acting GLP-1 receptor antagonist in Phase 2 for post-bariatric hypoglycemia. MBX 4291 targets obesity in IND-enabling studies. Founded 2018, Carmel, Indiana.

Company score

Sentiment: 0.22; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.15; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive